Catherine Bollard, MD, MBChB Blood and Marrow Transplant Specialist

Bio

Biography

Catherine M. Bollard, MBChB, MD, FRACP, FRCPA, is a senior scientist in the Center for Cancer and Immunology Research at the Children’s Research Institute, a member of the Division of the Blood and Marrow Transplantation, and the Principal Investigator and Co-Director of the Immunology Initiative of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System. In this role, she will lead clinical and research efforts to fight cancer and other inflammatory diseases by strengthening a child’s immune system.

A distinguished hematologist and immunotherapist, Dr. Bollard’s research interests focus on three different areas including developing cell and gene therapies for patients with cancer and underlying immune deficiencies. She also is interested in stem cell and cord blood transplantation, and improving outcomes by decreasing infectious complications and preventing relapse. She also has a specific interest in cell therapies for EBV-associated lymphomas and as head of the NHL committee of the Children’s Oncology Group is moving cell therapies to the cooperative group setting.

Education & Training

Education & Training

  • MD, 2005
    University of Otago
  • Fellowship Program, Peds Bone Marrow Transplant, 2001
    Texas Children's Hospital
  • Fellowship Program, Pediatric Hematology/Oncology, 2000
    Auckland University Hospital
  • Residency Program, Pediatric Hematology/Oncology, 1994
    Saint Bartholomew's Hospital
  • Residency Program, General Medicine, 1993
    Auckland University Hospital
  • MBCHB, 1991
    University of Otago
News

News

Research & Publications

Research & Publications

Adenovirus hexonspecific CD4 and CD8 T cell epitopes for vaccine and immunotherapy

(2008) Virol

Complete Responses of Relapsed Lymphoma Following Genetic Modification of TumorAntigen Presenting Cells and Tlymphocyte transfer

(2007) Blood

Cytotoxic T Lymphocyte Therapy With Donor T Cells Prevents And Treats Adenovirus And EpsteinBarr Virus Infections After Haploidentical And Matched Unrelated Stem Cell Transplant

(2009) Blood

De novo Tlymphocyte responses against baculovirusderived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination

(2009) Vaccine

Functionally Active VirusSpecific TCells that target CMV Adenovirus and EBV can be Expanded From Naïve T Cell Populations in Cord Blood and will Target a Broad Range of Viral Epitopes

(2009) Blood

Generation of multileukemia antigenspecific T cells to enhance the graftversusleukemia effect after allogeneic stem cell transplant

(2013) Leukemia

Improving T cell therapy for relapsed EBV negative Hodgkins Lymphoma by targeting upregulated MAGEA4

(2011) Clin Cancer Res

Infusion of donorderived CD19redirected virusspecific T cells for Bcell malignancies relapsed after allogeneic stem cell transplant a phase 1 study

(2013) Blood

Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised patients

(2006) Nature Medicine

The use of EBVspecific Cytotoxic T cells for EBVve Hodgkin Disease

(2004) Exp Medicine

View publications on PubMed

Invest in future cures for some of life's most devastating diseases

See other ways to give

Keep in touch with Children's National by signing up for our newsletters.

Sign up now

Andrew's Story

Patient story

"Our best advice is to take each episode as it comes, and you will get through them all! It may sound like a cliché, but you do learn to live one day at a time and to relish every small milestone in your child's life."

Read More of Andrew's Story